Last reviewed · How we verify
RMP-A03 - Dose 1
RMP-A03 - Dose 1 is a Small molecule drug developed by Suzhou Raymon Pharmaceuticals Company, Ltd.. It is currently in Phase 2 development.
RMP-A03 - Dose 1 is an intervention being studied in a Phase 2a clinical trial for the treatment of pterygium. The trial, NCT05794204, is evaluating the safety and efficacy of RMP-A03 Ocular Suspension in patients with pterygium.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | RMP-A03 - Dose 1 |
|---|---|
| Sponsor | Suzhou Raymon Pharmaceuticals Company, Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RMP-A03 - Dose 1 CI brief — competitive landscape report
- RMP-A03 - Dose 1 updates RSS · CI watch RSS
- Suzhou Raymon Pharmaceuticals Company, Ltd. portfolio CI
Frequently asked questions about RMP-A03 - Dose 1
What is RMP-A03 - Dose 1?
Who makes RMP-A03 - Dose 1?
What development phase is RMP-A03 - Dose 1 in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing